RU2020122659A - Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения - Google Patents
Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения Download PDFInfo
- Publication number
- RU2020122659A RU2020122659A RU2020122659A RU2020122659A RU2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A RU 2020122659 A RU2020122659 A RU 2020122659A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- formula
- lipoic
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841004306 | 2018-02-05 | ||
| IN201841004306 | 2018-02-05 | ||
| IN201841008091 | 2018-03-05 | ||
| IN201841008091 | 2018-03-05 | ||
| PCT/IB2019/050901 WO2019150341A1 (en) | 2018-02-05 | 2019-02-05 | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020122659A true RU2020122659A (ru) | 2022-03-09 |
| RU2020122659A3 RU2020122659A3 (enExample) | 2022-07-08 |
Family
ID=67480013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020122659A RU2020122659A (ru) | 2018-02-05 | 2019-02-05 | Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200375961A1 (enExample) |
| EP (1) | EP3749303A4 (enExample) |
| JP (1) | JP2021512876A (enExample) |
| KR (1) | KR20200118128A (enExample) |
| AU (1) | AU2019214557A1 (enExample) |
| BR (1) | BR112020015436A2 (enExample) |
| CA (1) | CA3089894A1 (enExample) |
| IL (1) | IL276350A (enExample) |
| MX (1) | MX2020008173A (enExample) |
| RU (1) | RU2020122659A (enExample) |
| SG (1) | SG11202006492SA (enExample) |
| WO (1) | WO2019150341A1 (enExample) |
| ZA (1) | ZA202004058B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265791B (en) * | 2016-10-04 | 2022-07-01 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
| DK3870170T3 (da) | 2018-10-26 | 2026-05-26 | Opus Genetics Inc | Behandling af presbyopi og mydriasis med fentolamin |
| US20220096467A1 (en) * | 2019-01-12 | 2022-03-31 | Cellix Bio Provate Limited | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
| CN113387923A (zh) * | 2020-03-13 | 2021-09-14 | 诺华股份有限公司 | 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法 |
| IL298476A (en) * | 2020-05-26 | 2023-01-01 | Cellix Bio Private Ltd | Pharmaceutical formulations of pilocarpine r-(+)-lipoate |
| WO2022080529A1 (ko) * | 2020-10-15 | 2022-04-21 | 경상대학교병원 | 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| WO2023052977A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Compositions, methods and uses thereof |
| WO2023052974A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Ocular compositions and methods for the treatment of ophthalmic diseases and disorders |
| CN119454700A (zh) * | 2022-01-18 | 2025-02-18 | 苏州普乐康医药科技有限公司 | 一种含西维美林的眼用制剂及其制备方法和应用 |
| TWI916635B (zh) * | 2022-01-25 | 2026-03-01 | 張金明 | 西維美林水溶液組合物和使用方法 |
| US20250154135A1 (en) * | 2022-01-29 | 2025-05-15 | Nanjing Gritpharma Co., Ltd. | M-choline receptor agonist compound, preparation method therefor and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3608073A (en) * | 1968-07-16 | 1971-09-21 | Barnes Hind Pharm Inc | Emulsion of pilocarpine for ophthalmic use |
| US8673964B2 (en) * | 2004-05-20 | 2014-03-18 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
| US20110150974A1 (en) * | 2004-08-06 | 2011-06-23 | Daiichi Pharmaceutical Co., Ltd. | Agent For Oral Mucosal Administration |
| JP2006070027A (ja) * | 2004-08-06 | 2006-03-16 | Dai Ichi Seiyaku Co Ltd | 口腔粘膜投与剤 |
| WO2007064755A2 (en) * | 2005-11-30 | 2007-06-07 | Endo Pharmaceuticals Inc. | Treatment of xerostomia with a sulfur-containing antioxidant |
| UA86441C2 (ru) * | 2007-03-30 | 2009-04-27 | Акционерное Общество Открытого Типа "Галичфарм" | (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе |
| US20090263467A1 (en) * | 2008-04-21 | 2009-10-22 | Hemant Narahar Joshi | Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments |
| ES2579173T3 (es) * | 2009-06-15 | 2016-08-05 | Encore Health, Llc | Ésteres de colina para tratar presbicia y cataratas |
| ES2443847T3 (es) * | 2009-11-12 | 2014-02-20 | Acacia Pharma Limited | Uso de betanecol para el tratamiento de xerostomía |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| JP2015533174A (ja) * | 2012-10-11 | 2015-11-19 | セラヴィダ，インコーポレイテッド | ピロカルピンの医薬製剤 |
| KR101586789B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| US9427144B2 (en) * | 2014-01-03 | 2016-08-30 | Ophthalmx Llc | Methods and systems for detecting ophthalmic disease |
| US20160317606A1 (en) * | 2014-01-06 | 2016-11-03 | Stealth Bio Therapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
| IL265791B (en) * | 2016-10-04 | 2022-07-01 | Cellix Bio Private Ltd | Compositions and methods for the treatment of xerostomia |
| BR112020009361A2 (pt) * | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| US20220096467A1 (en) * | 2019-01-12 | 2022-03-31 | Cellix Bio Provate Limited | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
-
2019
- 2019-02-05 EP EP19747106.3A patent/EP3749303A4/en not_active Withdrawn
- 2019-02-05 MX MX2020008173A patent/MX2020008173A/es unknown
- 2019-02-05 SG SG11202006492SA patent/SG11202006492SA/en unknown
- 2019-02-05 RU RU2020122659A patent/RU2020122659A/ru unknown
- 2019-02-05 WO PCT/IB2019/050901 patent/WO2019150341A1/en not_active Ceased
- 2019-02-05 BR BR112020015436-9A patent/BR112020015436A2/pt not_active Application Discontinuation
- 2019-02-05 AU AU2019214557A patent/AU2019214557A1/en not_active Abandoned
- 2019-02-05 KR KR1020207025451A patent/KR20200118128A/ko not_active Ceased
- 2019-02-05 JP JP2020542141A patent/JP2021512876A/ja active Pending
- 2019-02-05 CA CA3089894A patent/CA3089894A1/en active Pending
-
2020
- 2020-07-02 ZA ZA2020/04058A patent/ZA202004058B/en unknown
- 2020-07-28 IL IL276350A patent/IL276350A/en unknown
- 2020-08-04 US US16/985,187 patent/US20200375961A1/en not_active Abandoned
-
2022
- 2022-11-23 US US17/993,868 patent/US20230310391A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020008173A (es) | 2020-09-25 |
| BR112020015436A2 (pt) | 2020-12-22 |
| EP3749303A1 (en) | 2020-12-16 |
| KR20200118128A (ko) | 2020-10-14 |
| SG11202006492SA (en) | 2020-08-28 |
| US20200375961A1 (en) | 2020-12-03 |
| US20230310391A1 (en) | 2023-10-05 |
| CA3089894A1 (en) | 2019-08-08 |
| EP3749303A4 (en) | 2022-01-26 |
| IL276350A (en) | 2020-09-30 |
| WO2019150341A1 (en) | 2019-08-08 |
| JP2021512876A (ja) | 2021-05-20 |
| AU2019214557A1 (en) | 2020-08-20 |
| ZA202004058B (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512876A5 (enExample) | ||
| ES2743153T3 (es) | Métodos para tratar el síndrome de fibromialgia | |
| ES2927675T3 (es) | Tratamiento de la cataplexia | |
| JP2004526745A5 (enExample) | ||
| ES2729713T3 (es) | Compuestos tricíclicos, composiciones que los comprenden y usos de los mismos | |
| AU2014209387A1 (en) | Toxic aldehyde related diseases and treatment | |
| RU2019113465A (ru) | Композиции и способы лечения ксеростомии | |
| RU2005131995A (ru) | Композиции, содержащие жирные кислоты и аминокислоты | |
| ES2979262T3 (es) | Composiciones que comprenden metilfenidato-profármacos, procesos de elaboración y uso de las mismas | |
| CN102421288A (zh) | 前列环素类似物的固体剂型 | |
| CA3089894A1 (en) | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof | |
| JP2022191331A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
| CN103228618B (zh) | 新化合物及其医药用途 | |
| TW201538155A (zh) | 活性成份輔助組成物及將活性成份化合物遞送給對象之方法 | |
| JP2019517582A (ja) | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 | |
| JP2025163212A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| AR076848A1 (es) | Combinacion antitumoral que comprende ave8062 y sorafenib | |
| US20170319519A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| WO2016020919A1 (en) | Compositions comprising tricyclic compounds, and uses thereof | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2023518640A5 (enExample) | ||
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| RU2005138369A (ru) | Фармацевтически полезные соли производных карбоновой кислоты | |
| JP2005523269A5 (enExample) | ||
| JP2023522866A5 (enExample) |